Natco Pharma gets 9 observations from US drugs regulator for Kothur plant
The Food and Drug Administration's observations were procedural and "can be addressed within a short period of time", says Natco.06-06-2019
Natco Pharma gets 9 observations from US drugs regulator for Kothur plant
The Food and Drug Administration's observations were procedural and "can be addressed within a short period of time", says Natco.NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
USFDA COMPLETES INSPECTION OF NATCO's KOTHUR FORMULATION FACILITYNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco files ANDA for Bosentan 32mg Tablets for the USA marketNatco Pharma: Pact with Onyx bodes well
Shares of Natco Pharma may remain in focus, as it has reached a settlement with Onyx Therapeutics, Inc on patent litigation related to generic versionNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO settles generic Carfilzomib Injection Patent Litigation in the US marketNatco Pharma Ltd - 524816 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 01/04/2018 2Date of Report31/03/2019 3 Name of the Certifying Firm BK & Associates 4 Name of the Certifying Individual B Kiran Kumar 5Membership TypeACS 6 Membership Number 29116 7 CP No. 15876 8 Whether any observations/qualification reported by the Secretarial Auditor ? NONatco Pharma slips 8% on weak Q4 results; stock hits new low
The company's consolidated net profit more-than-halved at Rs 120 crore in March quarter against Rs 300 crore in the year-ago quarter.Natco Pharma Ltd - 524816 - Record Date Fixed As 7Th June, 2019 For Payment Of Third Interim Dividend
Record date fixed as 7th June, 2019 for Payment of third Interim DividendNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Appointment of Statutory AuditorsNATCO PHARMA LTD. - 524816 - Results For The Financial Year 18-19
Results For the Financial Year 18-19